Journal Information
Vol. 11. Issue 3.
Pages 327-335 (May - June 2005)
Share
Share
Download PDF
More article options
Vol. 11. Issue 3.
Pages 327-335 (May - June 2005)
Caso Clínico\Clinical Case
Open Access
Uma criança com hipertensão pulmonar: Da investigação etiológica à orientação terapêutica
A child with pulmonary hypertension: From etiological study to therapeutic decisions
Visits
4858
Micaela Guardiano1,
Corresponding author
mguardiano@hotmail.com

Correspondência: Micaela Guardiano, Departamento de Pediatria (Director: Professor Dr. Álvaro Aguiar), Hospital de S. João, Tel: 918721448.
, Ana Maria Maia2, Cíntia Correia3, Inês Azevedo4, Ana Rosa Lopes5, Eduardo Dias da Silva6, Conceição Souto Moura7, António Marinho8
1 Interna Complementar de Pediatria – Serviço de Pediatria, Hospital de S. João
2 Assistente Hospitalar - Serviço de Pediatria, Hospital de S. João
3 Assistente Hospitalar Eventual - Serviço de Pediatria, Hospital de S. João
4 Assistente Hospitalar Graduada – Unidade de Pneumologia, Serviço de Pediatria, Hospital de S. João
5 Assistente Hospitalar Eventual – Unidade de Cuidados Intensivos Pediátricos, Hospital de S. João
6 Assistente Hospitalar Graduado – Serviço de Cardiologia Pediátrica, Hospital de S. João
7 Assistente Hospitalar – Serviço de Anatomia Patológica, Hospital de S. João
8 Assistente Hospitalar Graduado – Serviço de Cardiologia Pediátrica, Hospital da Universidade de Coimbra
This item has received

Under a Creative Commons license
Article information
Resumo

A hipertensão pulmonar (HP) constitui uma entidade rara mas devastadora, com mau prognóstico e elevada mortalidade. Para além da forma idiopática e familiar, a HP pode associarse a uma grande variedade de patologias, mas constitui um diagnóstico raro em idade pediátrica.

Os autores apresentam o caso de uma criança de 4 anos, admitida no departamento de Pediatria do Hospital de S. João, para investigação de síncope. Logo na admissão foi feito o diagnóstico ecográfico de HP. O estudo diagnóstico ulterior permitiu identificar doença pulmonar previamente desconhecida (bronquiolite obliterante).

A terapêutica neste caso consistiu na associação de um antagonista dos canais de cálcio, o diltiazem, com um antagonista dos receptores da endotelina, o bosentan, e com oxigenioterapia contínua.

Este é o primeiro caso de bronquiolite obliterante diagnosticado no nosso Serviço na sequência do estudo etiológico de HP. Neste caso não foi possível determinar o evento desencadeante da doença pulmonar.

Rev Port Pneumol 2005; XI (3): 327-335

Palavras-chave:
Hipertensão pulmonar
etiologia
terapêutica
bronquiolite obliterante
Abstract

Pulmonary hypertension is a rare but devastating disease, with poor prognosis and high mortality. The disease may present as Primary Pulmonary Hypertension where no clear aetiology can be identified, or be related to a variety of underlying conditions. This is a rare disease in paediatric age.

The authors present the clinical case of a 4 years old child, admitted in Paediatric Department of S. João Hospital for syncope episode. The diagnosis of pulmonary hypertension was made by echocardiogram. Ulterior studies revealed pulmonary disease (obliterans bronchiolitis).

The treatment included a calcium channel blocker (diltiazem), an endothelin antagonist (bosentan) and supplemental oxygen.

This is the first case of obliterans bronchiolitis diagnosed during etiological study for pulmonary hypertension, in our Pediatric‘s Department. In this case we could not determine the pulmonary disease precipitating event.

Rev Port Pneumol 2005; XI (3): 327-335

Key words:
Pulmonary hypertension
aetiology
treatment
obliterans bronchiolitis
Full text is only aviable in PDF
Bibliografia
[1.]
A. Widlitz, R.J. Barst.
Pulmonary arterial hypertension in children.
Eur Respir J, 21 (2003), pp. 155-176
[2.]
R. Wensel, C.F. Opitz, R. Ewert, L. Bruch, F.X. Kleber.
Effects of Iloprost inhalation on exercise capacity and ventilatory efficiency in patients with primary pulmonary hypertension.
Circulation, 101 (2000), pp. 2388
[3.]
G. Simonneau, N. Galiè, L.J. Rubin, D. Langleben, W. Seeger, G. Domenighetti, et al.
Clinical classification of Pulmonary Hypertension.
Journal of the American College of Cardiology, vol 43 (2004), pp. 5S-12S
[4.]
S. Rich, B.H. Brundage.
High dose calcium channel blocking therapy for primary pulmonary hypertension: evidence for long term reduction in pulmonary artery pressure and regression of right ventricular hypertrophy.
Circulation, 76 (1987), pp. 135-141
[5.]
S. Rich, E. Kaufmann, P.S. Levy.
The effect of high doses of calcium channel blockers on survival in primary pulmonary hypertension.
N England J Med, 327 (1992), pp. 76-81
[6.]
D. O‘Callaghan, S.P. Gaine.
Bosentan: a novel agent for the treatment of pulmonary arterial hypertension.
J Clin Pract, 58 (2004), pp. 69-73
[7.]
O. Sitbon, et al.
Who benefits from long-term calcium channel blocker therapy in primary pulmonary hypertension? Presented at the American Thoracic Society Meeting, Seattle, 19.
(May, 2003),
[8.]
R.J. Barst, L.J. Rubin, W.A. Long, M.D. McGoon, S. Rich, D.B. Badesch, et al.
A comparison of continuous intravenous epoprostenol (prostacyclin) with conventional therapy for primary pulmonary hypertension.
The Primary Pulmonary Hypertension Study Group. N Engl J Med, 334 (1996), pp. 296-302
[9.]
H. Olschewski, B. Rohde, J. Behr, R. Ewert, T. Gessler, A. Ghofrani, T. Schmehl.
Pharmacodynamics and pharmacokinetics of inhaled iloprost, aerosolized by three different devices, in severe pulmonary hypertension.
Chest, 124 (2003), pp. 1294-1304
[10.]
S.W. Allen, B.A. Chatfield, S.A. Koppenhafer, M.S. Schaffer, R.R. Wolfe, S.H. Abman.
Circulation immunoreactive endothelin-1 in children with pulmonary hypertension.
Association with acute hypoxic pulmonary vasoreactivity. Am Rev Respir Dis, 148 (1993), pp. 519-522
[11.]
O. Sitbon, D.B. Badesch, R.N. Channick, A. Frost, I.M. Robins, G. Simonneau, et al.
Effects of the dual endothelin receptor antagonist bosentan in patients with pulmonary arterial hypertension – a 1 year follow-up study.
Chest, 124 (2003), pp. 247-254
[12.]
R.N. Channick, O. Sitbon, I.M. Robins, A. Frost, V.F. Tapson, et al.
Effects of the dual endothelin-receptor antagonist bosentan in patients with pulmonary hypertension: a randomised placebo-controlled study.
Lancet, 358 (2001), pp. 1119-1123
[13.]
L.J. Rubin, D.B. Badesch, R.J. Barst, N. Galie, C.M. Black, A. Keogh, et al.
Bosentan therapy for primary pulmonary hypertension.
N Engl J Med, 346 (2002), pp. 896-903
[14.]
P.W.K. Chan, R. Muridan, J.A. Debruyne.
Bronchiolitis obliterans in children: clinical profile and diagnosis.
Respirology, 5 (2000), pp. 369-375
[15.]
C. Schelinger, S. Veeraraghavan, M.N. Koss.
Constructive (obliterative) bronchiolitis.
Curr Opin Pulm Med, 4 (1998), pp. 288-293
[16.]
T. Ezri, S. Kunichezky, A. Eliraz, D. Soroker, D. Halperin, A. Schattner.
Bronchiolitis obliterans – current concepts.
Q J Med, 87 (1994), pp. 1-10
Copyright © 2005. Sociedade Portuguesa de Pneumologia/SPP
Pulmonology
Article options
Tools

Are you a health professional able to prescribe or dispense drugs?